GoodRx (NASDAQ:GDRX) Stock Price Up 15.7% - Here's Why

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s stock price rose 15.7% during mid-day trading on Thursday . The stock traded as high as $3.82 and last traded at $3.7850. Approximately 2,064,694 shares changed hands during mid-day trading, a decline of 2% from the average session volume of 2,096,267 shares. The stock had previously closed at $3.27.

Wall Street Analysts Forecast Growth

• Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

GDRX has been the topic of several research analyst reports. TD Cowen boosted their target price on shares of GoodRx from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Weiss Ratings downgraded shares of GoodRx from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, July 23rd. Citigroup reaffirmed a "buy" rating on shares of GoodRx in a report on Thursday, July 23rd. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $3.50 price target on shares of GoodRx in a research report on Friday, May 8th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $3.81.

Get Our Latest Stock Report on GDRX

GoodRx Trading Up 14.5%

• This healthcare stock making a buzz with 160% growth

The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of 62.93, a PEG ratio of 1.55 and a beta of 1.60. The business's 50-day moving average price is $2.92 and its 200 day moving average price is $2.53. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting analysts' consensus estimates of $0.08. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The business had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. During the same period last year, the business earned $0.09 EPS. The business's revenue was down 1.3% on a year-over-year basis. On average, equities analysts forecast that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

• Gene therapy: Why does it cost millions for a single treatment?

Institutional investors have recently modified their holdings of the business. Essential Partners LLC boosted its holdings in GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after purchasing an additional 11,295 shares during the last quarter. Meridian Wealth Management LLC acquired a new position in shares of GoodRx in the 4th quarter valued at approximately $29,000. SG Americas Securities LLC purchased a new position in shares of GoodRx during the 1st quarter valued at approximately $29,000. Krilogy Financial LLC purchased a new position in shares of GoodRx during the 1st quarter valued at approximately $33,000. Finally, Quarry LP acquired a new stake in shares of GoodRx during the third quarter worth approximately $33,000. Institutional investors and hedge funds own 63.77% of the company's stock.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Further Reading

• Five stocks we like better than GoodRx
• McDonald's Stock Sell-Off: Justified Warning or Buying Opportunity?
• Why Brown-Forman Rejected a 23% Premium Twice
• Rocket Lab Lands a Wave of Contracts Ahead of Earnings
• Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GoodRx Right Now?

Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here